Jul 26, 2017

British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart

Posted by in categories: biotech/medical, life extension

When British billionaire Jim Mellon wants to map out an investment strategy, he likes to write a book first. Out of that process came his most recent work — Juvenescence: Investing in the Age of Longevity. Now he and some close associates with some of the best connections in biotech are using the book as inspiration to launch a new company — also named Juvenescence — with plans to make a big splash in anti-aging research.

Read more

Comments are closed.